{
    "id": 6189,
    "fullName": "ERBB3 V104L",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "ERBB3 (HER3) V104L lies within the extracellular domain of the Erbb3 (Her3) protein (UniProt.org). V104L confers a gain of function to the Erbb3 (Her3) protein as demonstrated by increased phosphorylation of Erbb3 (Her3) (PMID: 24909266), and increased downstream signaling, cell proliferation, colony formation, and migration in culture, and enhanced tumor growth in mouse models (PMID: 29954840).",
            "references": [
                {
                    "id": 9913,
                    "pubMedId": 24909266,
                    "title": "Mutational and expressional analysis of ERBB3 gene in common solid cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24909266"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 14332,
                    "pubMedId": 29954840,
                    "title": "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954840"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2065,
        "geneSymbol": "ERBB3",
        "terms": [
            "ERBB3",
            "c-erbB-3",
            "c-erbB3",
            "ErbB-3",
            "erbB3-S",
            "FERLK",
            "HER3",
            "LCCS2",
            "MDA-BF-1",
            "p180-ErbB3",
            "p45-sErbB3",
            "p85-sErbB3"
        ]
    },
    "variant": "V104L",
    "createDate": "05/16/2015",
    "updateDate": "07/31/2019",
    "referenceTranscriptCoordinates": {
        "id": 123517,
        "transcript": "NM_001982",
        "gDna": "chr12:g.56085070G>C",
        "cDna": "c.310G>C",
        "protein": "p.V104L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 16217,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tecentriq (atezolizumab) treatment of a gallbladder carcinoma cell line expressing ERBB3 (HER3) V104L and CD274 (PD-L1) resulted in reduced downstream signaling, decreased viability in a co-culture assay with peripheral blood mononuclear cells, and reduced tumor growth in a cell line xenograft mouse model (PMID: 29954840).",
            "molecularProfile": {
                "id": 31587,
                "profileName": "CD274 pos ERBB3 V104L"
            },
            "therapy": {
                "id": 1201,
                "therapyName": "Atezolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 4948,
                "name": "gallbladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14332,
                    "pubMedId": 29954840,
                    "title": "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16216,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sapitinib (AZD8931) treatment of gallbladder carcinoma cell lines expressing ERBB3 (HER3) V104L and CD274 (PD-L1) resulted in reduced downstream signaling, decreased viability in a co-culture assay with peripheral blood mononuclear cells, and reduced tumor growth and Cd274 (PD-L1) expression in a cell line xenograft mouse model (PMID: 29954840).",
            "molecularProfile": {
                "id": 31587,
                "profileName": "CD274 pos ERBB3 V104L"
            },
            "therapy": {
                "id": 910,
                "therapyName": "Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4948,
                "name": "gallbladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14332,
                    "pubMedId": 29954840,
                    "title": "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16219,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, combined Sapitinib (AZD8931) and Tecentriq (atezolizumab) treatment decreased viability of a gallbladder carcinoma cell line expressing ERBB3 (HER3) V104L and CD274 (PD-L1) in a co-culture assay with peripheral blood mononuclear cells, and reduced tumor growth and increase apoptosis in a cell line xenograft mouse model relative to either therapy alone (PMID: 29954840).",
            "molecularProfile": {
                "id": 31587,
                "profileName": "CD274 pos ERBB3 V104L"
            },
            "therapy": {
                "id": 7941,
                "therapyName": "Atezolizumab + Sapitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4948,
                "name": "gallbladder carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14332,
                    "pubMedId": 29954840,
                    "title": "Genomic ERBB2/ERBB3 mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29954840"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 6040,
            "profileName": "ERBB3 V104L",
            "profileTreatmentApproaches": [
                {
                    "id": 14774,
                    "name": "HER3 Inhibitor",
                    "profileName": "ERBB3 V104L"
                },
                {
                    "id": 14773,
                    "name": "HER2 Inhibitor",
                    "profileName": "ERBB3 V104L"
                },
                {
                    "id": 14779,
                    "name": "Trastuzumab",
                    "profileName": "ERBB3 V104L"
                },
                {
                    "id": 14778,
                    "name": "Pertuzumab",
                    "profileName": "ERBB3 V104L"
                },
                {
                    "id": 14772,
                    "name": "HER inhibitor (Pan)",
                    "profileName": "ERBB3 V104L"
                }
            ]
        },
        {
            "id": 31587,
            "profileName": "CD274 pos ERBB3 V104L",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 123517,
            "transcript": "NM_001982",
            "gDna": "chr12:g.56085070G>C",
            "cDna": "c.310G>C",
            "protein": "p.V104L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 123518,
            "transcript": "NM_001005915",
            "gDna": "chr12:g.56085070G>C",
            "cDna": "c.310G>C",
            "protein": "p.V104L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}